ADPT
Adaptive Biotechnologies Corporation
NASDAQ · Healthcare · Biotechnology · US
$24.28
−1.18%0
Insider buys (3m)
31
Insider sells (3m)
-$50.6M
Net value (3m)
-64.3%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 28, 2026 | OWEN KATEY EINTERZ · director | Sale | 9,615 | $26 |
| Aug 20, 2026 | HERSHBERG ROBERT · director | M-Exempt | 15,000 | $6.32 |
| Aug 20, 2026 | HERSHBERG ROBERT · director | Sale | 15,664 | $24 |
| Aug 20, 2026 | HERSHBERG ROBERT · director | Sale | 15,000 | $24 |
| Aug 19, 2026 | ROBINS CHAD M · director, officer: CEO and Chairman | M-Exempt | 321,324 | $6.55 |
| Aug 19, 2026 | ROBINS CHAD M · director, officer: CEO and Chairman | Sale | 318,799 | $25 |
| Aug 19, 2026 | ROBINS CHAD M · director, officer: CEO and Chairman | Sale | 2,525 | $26 |
| Aug 19, 2026 | ROBINS CHAD M · director, officer: CEO and Chairman | M-Exempt | 278,676 | $6.55 |
| Aug 19, 2026 | NEUPERT PETER M · director | M-Exempt | 15,000 | $6.32 |
| Aug 19, 2026 | NEUPERT PETER M · director | Sale | 15,000 | $25 |
| Aug 19, 2026 | NEUPERT PETER M · director | Sale | 40,000 | $25 |
| Aug 19, 2026 | NEUPERT PETER M · director | Sale | 69,690 | $25 |
| Aug 19, 2026 | ROBINS CHAD M · director, officer: CEO and Chairman | Sale | 204 | $25 |
| Aug 19, 2026 | ROBINS CHAD M · director, officer: CEO and Chairman | Sale | 278,472 | $24 |
| Aug 12, 2026 | BOBULSKY SUSAN · officer: Chief Commercial Officer, MRD | Sale | 3,000 | $25 |
| Aug 3, 2026 | BOBULSKY SUSAN · officer: Chief Commercial Officer, MRD | Sale | 1,299 | $24 |
| Jul 23, 2026 | ROBINS HARLAN S · officer: Chief Scientific Officer | Sale | 278,698 | $22 |
| Jul 23, 2026 | ROBINS HARLAN S · officer: Chief Scientific Officer | M-Exempt | 284,800 | $6.55 |
| Jul 23, 2026 | ROBINS HARLAN S · officer: Chief Scientific Officer | Sale | 213,702 | $22 |
| Jul 20, 2026 | BOBULSKY SUSAN · officer: Chief Commercial Officer, MRD | Sale | 5,000 | $23 |
| Jul 17, 2026 | LO FRANCIS · officer: Chief People Officer | Sale | 105,762 | $23 |
| Jul 17, 2026 | LO FRANCIS · officer: Chief People Officer | M-Exempt | 59,374 | $7.80 |
| Jul 17, 2026 | LO FRANCIS · officer: Chief People Officer | M-Exempt | 22,711 | $8.46 |
| Jul 17, 2026 | LO FRANCIS · officer: Chief People Officer | M-Exempt | 23,677 | $12 |
| Jul 7, 2026 | ROBINS HARLAN S · officer: Chief Scientific Officer | Sale | 146,889 | $22 |
| Jul 7, 2026 | ROBINS HARLAN S · officer: Chief Scientific Officer | Sale | 239,351 | $22 |
| Jul 6, 2026 | LO FRANCIS · officer: Chief People Officer | M-Exempt | 4,688 | $3.99 |
| Jul 6, 2026 | LO FRANCIS · officer: Chief People Officer | M-Exempt | 14,064 | $8.12 |
| Jul 6, 2026 | LO FRANCIS · officer: Chief People Officer | M-Exempt | 3,500 | $7.80 |
| Jul 6, 2026 | BOBULSKY SUSAN · officer: Chief Commercial Officer, MRD | Sale | 487 | $22 |
Institutional positioning
13F filings over the trailing two quarters
New 106Increased 214Reduced 186Sold out 43
| Filer | Action | Shares | Filed |
|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | Unchanged | 29,993,708 | Aug 14, 2026 |
| VIKING GLOBAL INVESTORS LP | Unchanged | 29,993,708 | May 15, 2026 |
| BlackRock, Inc. | Increased | 15,139,159 | Aug 7, 2026 |
| BLACKROCK, INC. | Reduced | 13,303,025 | May 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 6,403,587 | Aug 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 6,094,144 | May 15, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Increased | 5,911,366 | Aug 14, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | Increased | 5,476,231 | Aug 13, 2026 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | Increased | 5,436,718 | May 11, 2026 |
| D. E. Shaw & Co., Inc. | Increased | 4,625,859 | Aug 14, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | New Position | 4,491,474 | May 8, 2026 |
| INVESCO LTD. | Increased | 4,450,066 | May 12, 2026 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | Reduced | 4,267,645 | Aug 12, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Increased | 3,857,422 | May 15, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 3,641,837 | Aug 12, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 28, 2026